A 38-year-old woman with Graves' disease is started on antithyroid therapy. She develops a pruritic rash on day 3 of treatment with methimazole. Which feature best distinguishes a true drug allergy from a benign rash in this clinical context?

## Distinguishing True Allergy from Benign Rash in Antithyroid Therapy ### Clinical Presentation of Methimazole Rash **Key Point:** Methimazole causes rash in 1–5% of patients. Most rashes are benign, maculopapular, pruritic, and self-limited. However, true IgE-mediated hypersensitivity (urticaria, angioedema, respiratory involvement) indicates immediate discontinuation and is a contraindication to rechallenge. ### Comparison: Benign vs. Serious Rash | Feature | Benign Rash | True Allergy/Anaphylaxis | | --- | --- | --- | | **Type** | Maculopapular, pruritic | Urticaria, angioedema | | **Respiratory involvement** | Absent | Present (stridor, dyspnea) | | **Timing** | Days 3–7 (often resolves spontaneously) | Minutes to hours | | **Associated symptoms** | None or mild pruritus | Wheezing, throat tightness, hypotension | | **Management** | Continue drug + antihistamine | STOP immediately; cross-reactivity to PTU likely | | **Fever/lymphadenopathy** | Absent | May indicate drug reaction with eosinophilia (DRESS) | ### High-Yield Distinction **High-Yield:** Urticaria + angioedema + respiratory symptoms = true IgE-mediated hypersensitivity requiring drug cessation. This is the discriminating feature that mandates action. **Clinical Pearl:** A simple maculopapular pruritic rash on day 3 can often be managed conservatively with antihistamines while continuing the antithyroid drug. The patient should be counseled to report any worsening, respiratory symptoms, or facial swelling immediately. ### Management Algorithm ```mermaid flowchart TD A[Rash on methimazole]:::outcome --> B{Urticaria, angioedema,<br/>or respiratory symptoms?}:::decision B -->|Yes| C[STOP methimazole immediately]:::urgent B -->|No| D{Fever, lymphadenopathy,<br/>or systemic symptoms?}:::decision C --> E[Switch to PTU or iodine]:::action C --> F[Risk of cross-reactivity to PTU]:::outcome D -->|Yes| G[Consider DRESS syndrome]:::urgent D -->|No| H[Benign rash]:::outcome H --> I[Continue drug + antihistamine]:::action I --> J[Monitor for progression]:::action ``` ### Why This Matters True hypersensitivity (urticaria + angioedema + respiratory involvement) indicates IgE-mediated mast cell degranulation and carries risk of anaphylaxis. This is fundamentally different from a benign drug rash and requires immediate cessation. Cross-reactivity between methimazole and PTU is ~50%, so switching to PTU is risky in true allergy. [cite:Harrison 21e Ch 405; KD Tripathi 8e Ch 57]